Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Harpoon Therapeutics Doses First Patient with Anti-DLL3 T Cell Engager for Lung Cancer

americanpharmaceuticalreviewJanuary 11, 2021

Tag: Harpoon Therapeutics , TriTAC , lung cancer , DLL3 , HPN328

PharmaSources Customer Service